Event 3 – Lyon

This was a public meeting for participants with systems expertise seeking to lay out the interactions required for success and create a list of “signed -up alliance enthusiasts”

Avicenna event 3 in silico trials

Event 3 was held in Lyon

The Third Experts Meeting of the Avicenna project, took place at the Mercure Lyon Centre Saxe Lafayette Hotel in the aristocratic city of Lyon in east central France on Friday 31st of October 2014.

An optional social networking event on the previous evening included a presentation on local wines and a dinner at the famous l’ermitage Hotel overlooking the city. This event was the third in a planned series of five, helping to design a pathway towards the successful modernisation of the clinical trials process, making it leaner, quicker, more efficient and less expensive, that will ultimately be recommended to the Commission.

Avicenna event 3 in Lyon

Delegates enjoyed the beautiful architecture of Lyon

At this event we had the participation of 50 experts from industry, regulatory affairs and patient representative organisations, with experience of – or an interest in – the development and assessment of biomedical products and the R&D process that precedes them. The main goal of the event was to identify the research challenges related to the use of modelling and simulation technologies in the development of pharmaceutical products and medical devices. The first half of the day included presentations from six experts on the research challenges related to ISCT in pharma and devices. Each presentation was followed by a lively question and answer session.

During the second half of the day the meeting was organized into different brainstorming sessions in which we asked the attendees to voice their personal experiences in the field and to interact with others to identify research priorities in this area. These priorities will be recommended to the EC and other research funding agencies in order to increase the capability and usefulness of Computer Modelling & Simulation in the development and assessment of biomedical products; the goal is to define a research agenda that is driven by the needs of producers, regulators, medical professionals and patients. Delegates were asked to sign up to help edit/author the Roadmap that Avicenna is drafting and to agree Roadmap writing responsibilities.